Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
To evaluate quality of life in patients after 10 days pause of thyroid medication
 (Liothyronine) compared to treatment with recombinant TSH (Thyrogen) before radioiodine
 uptake and treatment in a double-blinded, randomised cross-over design.
Patients with a thyroid follicular or papillary cancer referred to radioiodine treatment in
 oncological department . The patients after thyroidectomy will be treated with Liothyronine
 and this treatment will be paused 10 days before radioiodine. As a routine these patients
 will be re-evaluated with iodine uptake 4 months later.

 The patients will be randomised to either T3 pause related to the first radioiodine treatment
 and Thyrogen injection (recombinant TSH) related to the second treatment/uptake - or Thyrogen
 related to the first treatment and T3 pause related to the second treatment /uptake.

 All medication given in the 10 days period right before radioiodine treatment/uptake will be
 delivered to the patients and marked with a protocol number. In the period with T3 pause the
 patients will be given placebo tablets and an injection of saline (instead of Thyrogen)
 before treatment/uptake at the similar time as given the Thyrogen injection. A nurse
 otherwise not involved in the study will give the injection.

 Patients will be evaluated by VAS, SF-36, and Eortc QLC30 (version 2.0) before radioiodine
 treatment and 3 weeks after treatment.
Inclusion Criteria:

 -  Follicular or papillary thyroid cancer

 Exclusion Criteria:

 -  < 18 or > 75 years old

 -  Pregnant or lactating women